Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1948 1
1949 1
1964 2
1965 6
1966 3
1967 4
1968 7
1969 5
1970 10
1971 3
1972 9
1973 4
1974 8
1975 7
1976 7
1977 9
1978 14
1979 2
1980 12
1981 15
1982 9
1983 8
1984 9
1985 12
1986 15
1987 9
1988 13
1989 17
1990 18
1991 27
1992 15
1993 14
1994 22
1995 19
1996 25
1997 24
1998 20
1999 36
2000 21
2001 23
2002 26
2003 20
2004 20
2005 26
2006 34
2007 29
2008 38
2009 40
2010 37
2011 36
2012 39
2013 44
2014 50
2015 46
2016 38
2017 39
2018 43
2019 43
2020 51
2021 58
2022 60
2023 45
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,277 results

Results by year

Filters applied: . Clear all
Page 1
The Amyloid-β Pathway in Alzheimer's Disease.
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. Hampel H, et al. Among authors: masters cl. Mol Psychiatry. 2021 Oct;26(10):5481-5503. doi: 10.1038/s41380-021-01249-0. Epub 2021 Aug 30. Mol Psychiatry. 2021. PMID: 34456336 Free PMC article. Review.
Alzheimer's disease.
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Masters CL, et al. Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Nat Rev Dis Primers. 2015. PMID: 27188934 Free article. Review.
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. Among authors: masters cl. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.
High performance plasma amyloid-β biomarkers for Alzheimer's disease.
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K. Nakamura A, et al. Among authors: masters cl. Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31. Nature. 2018. PMID: 29420472
The amyloid-β pathway in Alzheimer's disease: a plain language summary.
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. Hampel H, et al. Among authors: masters cl. Neurodegener Dis Manag. 2023 Jun;13(3):141-149. doi: 10.2217/nmt-2022-0037. Epub 2023 Mar 30. Neurodegener Dis Manag. 2023. PMID: 36994753 Free PMC article. Review.
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Li Y, et al. Among authors: masters cl. Neurology. 2022 Feb 15;98(7):e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14. Neurology. 2022. PMID: 34906975 Free PMC article.
Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Doré V, Singh AK, Wang P, Rainey-Smith S, Fowler C, Taddei K, Sohrabi HR, Molloy MP, Ames D, Maruff P, Rowe CC, Masters CL, Martins RN; AIBL Research Group. Chatterjee P, et al. Among authors: masters cl. Alzheimers Dement. 2023 Apr;19(4):1117-1134. doi: 10.1002/alz.12724. Epub 2022 Jul 21. Alzheimers Dement. 2023. PMID: 36574591
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, Hone E, Asih PR, Taddei K, Doré V, Villemagne VL, Sohrabi HR, Zetterberg H, Masters CL, Blennow K, Martins RN. Chatterjee P, et al. Among authors: masters cl. Alzheimers Dement. 2022 Jun;18(6):1141-1154. doi: 10.1002/alz.12447. Epub 2021 Sep 8. Alzheimers Dement. 2022. PMID: 34494715
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.
Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC, Karch CM, Xiong C, Allegri R, Mendez PC, Berman SB, Ikeuchi T, Mori H, Shimada H, Shoji M, Suzuki K, Noble J, Farlow M, Chhatwal J, Graff-Radford NR, Salloway S, Schofield PR, Masters CL, Martins RN, O'Connor A, Fox NC, Levin J, Jucker M, Gabelle A, Lehmann S, Sato C, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network. Barthélemy NR, et al. Among authors: masters cl. Nat Med. 2020 Mar;26(3):398-407. doi: 10.1038/s41591-020-0781-z. Epub 2020 Mar 11. Nat Med. 2020. PMID: 32161412 Free PMC article.
1,277 results